Indication
Essential Tremor
15 clinical trials
18 products
1 drug
Product
SAGE-324Clinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential TremorStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of PRAX-944 in the Treatment of Adults With Essential TremorStatus: Completed, Estimated PCD: 2023-02-09
Product
PRAX-944Product
PlaceboProduct
Prax-944Product
BOTOXClinical trial
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential TremorStatus: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults With Essential TremorStatus: Completed, Estimated PCD: 2022-03-24
Clinical trial
Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944) in Adults With Essential TremorStatus: Recruiting, Estimated PCD: 2024-09-01
Product
UlixacaltamideProduct
Part B: 120 mg PRAX-944Product
NT 201Clinical trial
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper LimbStatus: Completed, Estimated PCD: 2023-04-26
Clinical trial
A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential TremorStatus: Completed, Estimated PCD: 2021-02-01
Product
JZP385Clinical trial
A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential TremorStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Product
SPECTProduct
PETClinical trial
Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.Status: Recruiting, Estimated PCD: 2024-09-01
Product
PRAX-114Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of PRAX-114 in the Treatment of Adults With Essential TremorStatus: Withdrawn, Estimated PCD: 2022-06-30
Clinical trial
An Open-label Study of the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential TremorStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy ControlsStatus: Completed, Estimated PCD: 2021-12-20
Product
DaTSCAN IoflupaneClinical trial
A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential TremorStatus: Completed, Estimated PCD: 2017-11-22
Product
SAGE-217Clinical trial
The Mechanism of Tremor Modulating Properties of Propranolol and Primidone in Essential Tremor: A Study With Transcranial Magnetic Stimulation and Eye Blink Classical Conditioning ParadigmStatus: Completed, Estimated PCD: 2022-12-31
Product
PropranololProduct
PrimidoneClinical trial
Acamprosate and Methazolamide for Essential Tremor: a Randomized Clinical TrialStatus: Withdrawn, Estimated PCD: 2017-06-01
Product
AcamprosateDrug
VarlilumabProduct
Methazolamide